How do I transition from active treatment to surveillance for Lung Cancer

Transitioning from Active Treatment to Surveillance for Lung Cancer

This is an important question that marks a significant shift in your cancer care. Let me walk you through what this transition typically looks like, based on current medical guidelines.

Understanding the Transition

The shift from active treatment to surveillance means moving from receiving chemotherapy, radiation, or other cancer-fighting treatments to a monitoring phase where your care team watches for any signs of cancer returning. This doesn't mean your cancer care ends—it changes focus.

According to the NCCN Guidelines for Non-Small Cell Lung Cancer, surveillance is recommended for eligible patients with no evidence of disease after completing definitive therapy. The goal is to catch any recurrence early when treatment options may still be curative.

---

What Happens at the End of Active Treatment

Response Assessment First

Before surveillance begins, your oncology team will assess how well your treatment worked:

• Imaging studies (CT scans with contrast of your chest, abdomen, and pelvis)
• Brain MRI (preferred) or brain CT with contrast—this is important because lung cancer can spread to the brain
• Blood work as clinically indicated
• Physical examination by your oncologist

This "end-of-treatment" assessment establishes a baseline for comparison during surveillance.

---

Surveillance Schedules Based on Your Situation

The surveillance plan depends on your stage of disease and type of treatment you received. Here's what the NCCN Guidelines recommend:

For Early-Stage NSCLC (After Surgery or Radiation)

Years 1-2:

• Chest CT scan with contrast every 3-6 months
• History and physical exam at each visit

Years 3-5:

• Chest CT scan every 6-12 months
• Annual physical exams

After Year 5:

• Annual low-dose CT scans (without contrast)
• Annual physical exams

For Locally Advanced NSCLC (After Chemoradiation)

Similar schedule, though your team may recommend more frequent imaging initially depending on your specific situation.

Important Note on Brain Surveillance

If you had brain imaging during treatment, your care team will determine whether you need:

• Regular brain MRI surveillance, OR
• Prophylactic cranial irradiation (PCI) followed by surveillance

This decision depends on your age, overall health, and other factors your doctor will discuss with you.

---

Key Principles During Surveillance

What Imaging Shows

According to NCCN Guidelines, low-dose CT is beneficial for identifying recurrences in patients previously treated for lung cancer. However:

• PET/CT scans are NOT routinely recommended for routine surveillance in asymptomatic patients
• PET may be useful if a CT scan shows something suspicious that could be either cancer recurrence or scar tissue from radiation (called radiation fibrosis)
• Areas previously treated with radiation can remain "active" on PET scans for up to 2 years, so your doctor may need tissue confirmation (biopsy) if something looks concerning

What to Watch For

Between appointments, contact your care team immediately if you develop:

• New or worsening cough
• Chest pain
• Shortness of breath
• Coughing up blood
• Unexplained weight loss
• Persistent fatigue
• Neurological symptoms (headaches, balance problems, memory issues)

---

The Emotional Transition

Moving to surveillance can feel like a relief—treatment is over—but it can also bring anxiety about recurrence. This is completely normal. Many patients find it helpful to:

• Maintain regular follow-up appointments even when you feel well
• Keep a symptom log between visits
• Ask your team about survivorship care plans (the NCCN Guidelines recommend these after completing initial therapy)
• Discuss smoking cessation if applicable—this significantly improves outcomes

---

Questions to Ask Your Oncology Team

To personalize your surveillance plan, ask your doctor:

1. "Based on my specific stage and treatment, what is my surveillance schedule for the next 5 years?"

2. "What imaging will I need, and how often? Will I need brain MRI surveillance?"

3. "What symptoms should I report immediately between appointments?"

4. "Do I need any additional treatments after my primary therapy?" (For example, durvalumab immunotherapy is recommended for some patients after chemoradiation)

5. "What does a 'complete response' to my treatment mean, and do I have that?"

6. "Can you provide me with a written survivorship care plan that summarizes my treatment and follow-up schedule?"

7. "Are there any clinical trials I should consider during surveillance?"

---

Important Context

According to the NCCN Guidelines for Non-Small Cell Lung Cancer, recurrence is common after treatment, which is why surveillance is so important. However, the specific schedule and intensity of surveillance should be individualized based on:

• Your cancer stage at diagnosis
• Type and response to treatment
• Overall health and life expectancy
• Your preferences and ability to attend appointments

Your oncology team will determine the most appropriate surveillance approach for YOUR specific case based on the complete clinical picture.

---

Survivorship Resources

The NCCN Guidelines emphasize that patients transitioning to surveillance benefit from:

• Smoking cessation support (if applicable)
• Health monitoring for long-term side effects from treatment
• Counseling for wellness and health promotion
• Screening for other cancers as appropriate for your age and risk factors

Ask your care team about survivorship programs or resources available to you.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.